nach oben

Erschienen in:

16.12.2017 | Demenz | zertifizierte fortbildung

Neurodegenerative Erkrankungen

Neue Kriterien für die Diagnose der Demenz mit Lewy-Körpern

verfasst von: Adina Wagner, Eric Tönnies, Sebastian Sennock, Lisa Leikeim, Anna Gronewold, Johanna Klag, Prof. Dr. med. Richard Dodel

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die hohe Zahl Erkrankter macht die Demenzen mit Lewy-Körpern zu einem Thema von Relevanz. Für die Diagnose bleibt die klinische Symptomatik wichtigster Anhaltspunkt und noch immer kann die Erkrankung nur symptomatisch behandelt werden. Neue Möglichkeiten der Bildgebung und ein Umdenken hinsichtlich der Pathophysiologie bilden die Basis für interessante Neuentwicklungen.

McKeith, I.G., et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 2017. 89(1): p. 88–100. CrossRefPubMedPubMedCentral

Aarsland, D., Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord, 2016. 22 Suppl 1: p. S144–8. CrossRefPubMed

Howlett, D.R., et al., Regional multiple pathology scores are associated with cognitive decline in Lewy Body Dementias. Brain Pathol, 2015. 25(4): p. 401–8. CrossRefPubMed

Schulz-Schaeffer, W.J., Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s Disease? Biomolecules, 2015. 5(3): p. 1467–79. CrossRefPubMedPubMedCentral

Uchihara, T. and B.I. Giasson, Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol, 2016. 131(1): p. 49–73. CrossRefPubMed

Dettmer, U., D. Selkoe, and T. Bartels, New insights into cellular alpha-synuclein homeostasis in health and disease. Curr Opin Neurobiol, 2016. 36: p. 15–22. CrossRefPubMed

Sumi-Akamaru, H., et al., High expression of alpha-synuclein in damaged mitochondria with PLA2G6 dysfunction. Acta Neuropathol Commun, 2016. 4: p. 27. CrossRefPubMedPubMedCentral

Barthelemy, N.R., et al., differential mass spectrometry pofiles of Tau protein in the cerebrospinal fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. J Alzheimers Dis. 2016;51(4):1033–43. CrossRefPubMed

Lin, C.L., et al., Amyloid-beta suppresses AMP-activated protein kinase (AMPK) signaling and contributes to alpha-synuclein-induced cytotoxicity. Exp Neurol, 2016. 275 Pt 1: p. 84–98. CrossRefPubMed

10.

Pieri, L., et al., Cellular response of human neuroblastoma cells to alpha-synuclein fibrils, the main constituent of Lewy bodies. Biochim Biophys Acta, 2016. 1860(1 Pt A): p. 8–19. CrossRefPubMed

11.

Calo, L., et al., Synaptic failure and alpha-synuclein. Mov Disord, 2016. 31(2): p. 169–77. CrossRefPubMed

12.

Sampson, T.R., et al., Gut microbiota regulate motor deficits and neuroinflammation in a Model of Parkinson’s Disease. Cell, 2016. 167(6): p. 1469–1480 e12. CrossRefPubMedPubMedCentral

13.

Aldecoa, I., et al., Alpha-synuclein immunoreactivity patterns in the enteric nervous system. Neurosci Lett, 2015. 602: p. 145–9. CrossRefPubMed

14.

Wahlund, L.O., et al., Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Imaging, 2017. 8(1): p. 79–90. CrossRefPubMed

15.

Scheltens et al., Atrophy of medial temporal lobes on MRI in „probable“ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–72. CrossRefPubMedPubMedCentral

16.

Pasquier et al., Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268–72. CrossRefPubMed

17.

Harper, L., et al., MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain, 2016. 139(Pt 4): p. 1211–25. CrossRefPubMedPubMedCentral

18.

Papathanasiou, N.D., et al., Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord, 2012. 18(3): p. 225–9. CrossRefPubMed

19.

Shimizu, S., et al., Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer’s disease. Eur J Nucl Med Mol Imaging, 2016. 43(1): p. 184–92. CrossRefPubMed

20.

Brigo, F., G. Turri, and M. Tinazzi, 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. J Neurol Sci, 2015. 359(1-2): p. 161–71. CrossRefPubMed

21.

Treglia, G. and E. Cason, Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging, 2012. 22(2): p. 111–7. CrossRefPubMed

22.

Chiba, Y., et al., Early differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT. Psychiatry Res, 2016. 249: p. 105–12. CrossRefPubMed

23.

Walker, Z., et al., Lewy body dementias. Lancet, 2015. 386(10004): p. 1683–97. CrossRefPubMed

24.

Mishima, A., et al., Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis. J Alzheimers Dis, 2016. 50(1): p. 161–74. CrossRefPubMed

25.

Bousiges, O., et al., Diagnostic value of cerebrospinal fluid biomarkers (phospho-Tau181, total-Tau, Abeta42, and Abeta40) in prodromal stage of Alzheimer’s Disease and Dementia with Lewy Bodies. J Alzheimers Dis, 2016. 51(4): p. 1069–83. CrossRefPubMed

26.

Wang, Z.Y., et al., Use of CSF alpha-synuclein in the differential diagnosis between Alzheimer’s disease and other neurodegenerative disorders. Int Psychogeriatr, 2015. 27(9): p. 1429–38. CrossRefPubMed

27.

Petrova, M., et al., Investigation of neuropsychological characteristics of very mild and mild dementia with Lewy bodies. J Clin Exp Neuropsychol, 2016. 38(3): p. 354–60. CrossRefPubMed

28.

Heitz, C., et al., Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther, 2016. 8(1): p. 10. CrossRefPubMedPubMedCentral

29.

Chwiszczuk, L., et al., Higher frequency and complexity of sleep disturbances in Dementia with Lewy Bodies as compared to Alzheimer’s Disease. Neurodegener Dis, 2016. 16(3-4): p. 152–60. CrossRefPubMed

30.

Matsunaga, S., et al., Cholinesterase inhibitors for Lewy Body Disorders: A meta-analysis. Int J Neuropsychopharmacol, 2015. 19(2).

31.

Matsunaga, S., T. Kishi, and N. Iwata, Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry, 2015. 23(4): p. 373–83. CrossRefPubMed

32.

Wang, H.F., et al., Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry, 2015. 86(2): p. 135–43. CrossRefPubMed

33.

Stinton, C., et al., Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry, 2015. 172(8): p. 731–42. CrossRefPubMed

34.

Velayudhan L, Ffytche D, Ballard C, Aarsland D. New Therapeutic Strategies for Lewy Body Dementias. Curr Neurol Neurosci Rep. 2017;17(9):68 CrossRefPubMed

35.

Brand, S., et al., [Depression in Parkinson’s disease. Assessment and treatment]. Nervenarzt, 2007. 78(6): p. 715–27. CrossRefPubMed

36.

Pagan, F., et al., Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies. J Parkinsons Dis, 2016. 6(3): p. 503–17. CrossRefPubMedPubMedCentral

37.

Elder, G.J., et al., Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. Int Psychogeriatr, 2016. 28(2): p. 341–7. CrossRefPubMed

38.

Groot, C., et al., The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Res Rev, 2016. 25: p. 13–23. CrossRefPubMed

39.

Pena, J., et al., Improving functional disability and cognition in Parkinson disease: randomized controlled trial. Neurology, 2014. 83(23): p. 2167–74. CrossRefPubMedPubMedCentral

40.

Zhang, Q., Y.C. Kim, and N.S. Narayanan, Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci, 2015. 9: p. 293. PubMedPubMedCentral

Titel: Neurodegenerative Erkrankungen
Neue Kriterien für die Diagnose der Demenz mit Lewy-Körpern
verfasst von: Adina Wagner
Eric Tönnies
Sebastian Sennock
Lisa Leikeim
Anna Gronewold
Johanna Klag
Prof. Dr. med. Richard Dodel
Publikationsdatum: 16.12.2017
Verlag: Springer Medizin
Schlagwörter: Demenz
Parkinson-Krankheit
Demenz
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 12/2017
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-017-2088-2

Live-Webinar "Schulterschmerz in der Praxis gezielt managen"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2017

Verbesserung und Update der PML-Risikoberechnung

ADHS — Patientenaufklärung

Langfristige Stabilisierung mit subkutanen Immunglobulinen

Wieder da — Perampanel

1. Neuropädiatrie-Forum

Auch bei Suchterkrankung oder bipolarer Störung effektiv behandeln!